Clinical Trials
According to the International Clinical Trials Registry Platform under the World Health Organization (WHO) and clinicaltrials.gov under the U.S. National Institutes of Health the following trials should be recruiting at this moment (updated 30 September 2020):
A Long-Term Safety Study of BCX7353 in HAE – recruiting in Australia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, North Macedonia, Poland, Serbia, Slovakia, South Africa, South Korea, Spain, Switzerland, the United Kingdom, and the United States of America
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects with HAE Type I or II – recruiting in Austria, Czech Republic, Germany, Hungary, Italy, the Netherlands, North Macedonia, Poland, the United Kingdom, and the United States of America
A Study to Assess the Clinical Efficacy of IONIS-PKK- LRx in Participants with HAE – recruiting in the Netherlands, and the United States of America
An Extension Study of IONIS-PKK-LRx in Participants with HAE – recruiting in the United States of America
Biomarker for HAE Disease – recruiting in Armenia, Georgia, and Romania
C1 Inhibitor Registry in the Treatment of HAE Attacks – recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, and Sweden
Cloud-R HAE Registry – recruiting in France
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE – recruiting in the United States of America
Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population – recruiting in France
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants with HAE – recruiting in Japan
Epidemiological Analysis for HAE Disease – recruiting in Germany, Italy, Japan, Poland, Turkey, and the United Kingdom
Firazyr General Drug Use-Results Survey (Japan) – recruiting in Japan
Firazyr Patient Registry (Icatibant Outcome Survey – IOS) – recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Spain, Sweden, and the United Kingdom
Global Registry to Gather Data on Natural History of Patients with HAE Type I and II – recruiting in Italy
HAE Kininogen Assay – recruiting in Germany
Oral Berotralstat Expanded Access Program
Patient Registry to Evaluate the Real-world Safety of Ruconest – recruiting in the United States of America
Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants with HAE – recruiting in Canada, Puerto Rico, and the United States of America
Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants with HAE – recruiting in Austria, Germany, Switzerland, and the United Kingdom
The Role of the Coagulation Pathways in Recurrent Angioedema – recruiting in France
Read more about these and other clinical trials at https://clinicaltrials.gov and http://apps.who.int/trialsearch.
HAE related topics that might interest you
Global Access Program
Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program
Global Perspectives
Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community
HAEi Connect Member database
Free, secure online membership database and communications platform for HAEi’s member organizations
Regional Patient Advocates
Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized
Stay tuned – sign up for our newsletter
BE THE FIRST TO KNOW ABOUT HAE NEWS, TREATMENTS, EVENTS AND RELATED TOPICS